Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 124

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 124
---
 of 87,500 Common Shares at an exercise of $10.00 per share in a concurrent private placement. The common warrants were immediately exercisable upon issuance and will expire five years following the date of issuance.

On December 13, 2022, we issued 143,678 Common Shares and pre-funded warrants to purchase 143,678 Common Shares at a purchase price of $34.80 per Common Share and $34.80 per pre-funded warrant, for aggregate gross proceeds of $10 million.

On September 30, 2022, we issued 129,870 Common Shares, at a purchase price of $30.80 per share, and warrants to purchase up to an aggregate of 64,935 Common Shares at an exercise of $28.00 per share. At the closing of the offering, our existing short-term notes, with an aggregate principal balance of $1.53 million plus all accrued interest, that were issued in August 2022, were automatically converted into 62,911 Common Shares and the holders received 7,696 Common Shares issuable upon the exercise of the short term note original warrants, at an exercise of $19.88 per share, which expire 24 months following their issuance on August 19, 2022, and warrants to purchase up to 31,455 Common Shares with an exercise price of $28.00, that are exercisable six months after their issuance and will expire five years following the date that the warrants are initially exercisable.

On April 25, 2022, we issued warrants to purchase up to an aggregate of 78,750 Common Shares at an exercise of $41.60 per share. The warrants will be exercisable six months after their issuance and will expire five and a half years following their issuance. Upon the exercise of the warrants, the Company will create the respective amount of Common Shares.

<div align='center'>II-2</div>

Item 8. Exhibits and Financial Statement Schedules

Exhibits:

| Exhibit 
 Number  |     | Exhibit                                                                                                                                                                                                                                        
 Description                                                                                                                                                                                                                                    |
| 2.1     |     | Agreement                                                                                                                                                                                                                                      
 and Plan of Merger, dated November 4, 2024, by and between NLS Pharmaceutics, NLS Pharmaceutics (Israel Ltd.), and Kadimastem Ltd.                                                                                                             
 (filed as Exhibit 99.1 to Form 6-K (File No. 001-39957) filed November 5,